Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12944805 | 0.90 | KMT2A (0.38) | GRM7ALDH1A1MEN1KMT2ABACE1 | |
| SCHEMBL15870011 | 0.90 | GRM7 (0.36) | GRM7ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15869950 | 0.89 | PPARG (0.34) | ALDH1A1MEN1KMT2AAPEX1 | |
| SCHEMBL12944977 | 0.89 | GRM7 (0.37) | GRM7ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15869996 | 0.87 | SMN1; SMN2 (0.36) | GRM7ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12944969 | 0.87 | BCHE (0.39) | GRM7ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12944971 | 0.86 | HDAC1 (0.33) | GRM7ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17337195 | 0.85 | SIGMAR1 (0.39) | GRM7ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL17337296 | 0.85 | SIGMAR1 (0.39) | GRM7ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL15861733 | 0.84 | L3MBTL1 (0.32) | GRM7ALDH1A1SMN1; SMN2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642869-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20140194385-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2010130708-A9 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194385-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BPGM, GCG, GBA1 | GRM7 3198/4885ALDH1A1 1448/4885SMN1; SMN2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.